
Teva Pharmaceutical (TEVA) Stock Forecast & Price Target
Teva Pharmaceutical (TEVA) Analyst Ratings
Bulls say
Teva Pharmaceutical Indus is in a strong position to continue its growth trajectory in the generic drug market, as it maintains a significant presence in North America, Europe, Japan, Russia, and Israel. The recent acquisition of Emalex strengthens Teva's portfolio with a first-in-class asset targeting the pediatric Tourette population. The company is focused on developing innovative medicines and has a pipeline of potential treatments in neurology and immunology. With its strong financials and strategic initiatives in place, Teva has the potential for significant growth and impact in the pharmaceutical industry.
Bears say
Teva Pharmaceutical Indus is facing several challenges that may hinder its future growth prospects. The recent order to delist five patents for its ProAir HFA inhaler device could result in increased competition from generic versions, while its acquisition of businesses and ongoing legal issues could add further financial strain. Additionally, although Teva's innovative portfolio has shown strong performance, there is uncertainty surrounding regulation and pricing policies that could impact its margins and earnings.
This aggregate rating is based on analysts' research of Teva Pharmaceutical and is not a guaranteed prediction by Public.com or investment advice.
Teva Pharmaceutical (TEVA) Analyst Forecast & Price Prediction
Start investing in Teva Pharmaceutical (TEVA)
Order type
Buy in
Order amount
Est. shares
0 shares